Aeterna Zentaris Projects 2010 Filing, 2011 Launch For BPH Candidate
This article was originally published in The Pink Sheet Daily
Executive Summary
Canadian biotech accelerates cetrorelix development while boosting cash-burn guidance.
You may also be interested in...
With Royalty Stream Purchase, Cowen Is Bullish On Cetrotide In Fertility Market
Aeterna Zentaris, facing cash-burn woes, sells off royalties for funding to advance top two pipeline candidates.
With Royalty Stream Purchase, Cowen Is Bullish On Cetrotide In Fertility Market
Aeterna Zentaris, facing cash-burn woes, sells off royalties for funding to advance top two pipeline candidates.
Aeterna Shifts Directions Again; CEO And Senior VP Depart
Interim CEO says Canadian biotech will continue development of prostate cancer drug and seek to divest additional non-core assets.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: